Fundraising FoxDeerfield Management Company — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in
Co-investorsLumira VenturesS3 VenturesSV Health InvestorsJohnson & Johnson Innovation – JJDC
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)Zoar Engelman, PhD(President & CEO)Chad Hoskins(President & Chief Executive Officer)
BoardPaul LaViolette(Director)in
Board seatAndrew ElBardissi· per SEC Form D · $15M raise · filed Feb 2019
Co-investorsStar51 CapitalAction Potential Venture Capital Ltd.Earlybird Venture CapitalSV Health Investors
Cambridge, US
Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in
BoardBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)
Co-investorsAstellas Venture Management LLCCowen Healthcare InvestmentsIMM InvestmentK2 HealthVenturesMPM BioImpactSphera Funds Management
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.